Stem cell good news: CIRM funds new cutting edge studies

CIRM announced recently the funding of a number of exciting new studies.

ViaCyte received additional funding to support its development of its hESC-based pancreatic progenitor cell product PEC-Direct clinic trials. This work is very promising. CIRM also funded additional diabetes-related research by Humacyte on engineering blood vessels for use in dialysis, which is very creative.

VC-01 post-implant final

VC-01 post-implant

I was happy to see that my colleague here at UC Davis School of Medicine, Professor David Segal, received funding for a cutting edge grant on using gene editing for Angolan Syndrome. The grant is entitled, “MSC delivery of an artificial transcription factor to the brain as a treatment for Angelman Syndrome”.

This funding along with a new grant for Jeanne Loring on stem cells for Parkinson’s came via CIRM’s new basic biology type of funding mechanism. A number of other cool projects got funded via this RFA including one by David Schaeffer at Berkeley on stem cell-produced oligodendrocyte precursor cells to treat neurological injury.

This all is very good news for the stem cell field.

4 thoughts on “Stem cell good news: CIRM funds new cutting edge studies

Leave a Reply